<unk>  is used to treat relapsed or refractory, low grade or transformed B cell non-Hodgkin's lymphoma (NHL), a lymphoproliferative disorder, and previously untreated follicular NHL in adult patients who achieve a partial or complete response to first-line chemotherapy. The treatment should not be administered to patients with ≥25% lymphoma marrow involvement and/or impaired bone marrow reserve. The treatment starts with an infusions of rituximab. This may be followed by an administration of indium-111 labelled<unk>  (111In replaces the 90Y component) to allow the distribution of the drug to be imaged on a gamma camera, before the actual therapy is administered. Seven to nine days later, a second infusion of rituximab is given, followed by the 90Y-ibritumomab<unk> , by intravenous infusion over around 10 minutes. The radioactive activity is determined based on patient body weight and platelet count. Mechanism of action The antibody binds to the CD20 antigen found on the surface of normal and malignant B cells (but not B cell precursors), allowing radiation from the attached isotope (mostly beta emission) to kill it and some nearby cells. In addition, the antibody itself may trigger cell death via antibody-dependent cell-mediated cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and apoptosis. Together, these actions eliminate B cells from the body, allowing a new population of healthy B cells to develop from lymphoid stem cells.
Ibritumomab tiuxetan
Tositumomab
Loncastuximab tesirine
Axitinib
Fostamatinib
Tucatinib
Neratinib
Dasatinib